GENEVA, April 5, 2016 -- ObsEva, a Swiss biopharmaceutical company innovating women's reproductive health and pregnancy therapeutics, today announced th Annual Needham Healthcare Conference on Tuesday, April 12, 2016 at 9:00 a.m. ET at the Westin Grand Central Hotel in New York City.
About ObsEva
ObsEva is a biopharmaceutical company innovating women's reproductive health and pregnancy therapeutics from conception to birth. Between the ages of 20 and 50, millions of women worldwide suffer from reproductive health conditions that affect their quality of life and their ability to conceive or may lead to complications during pregnancy. ObsEva aims to improve upon the current treatment landscape with the development of novel, oral medicines with potentially best-in-class safety and efficacy profiles. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with multiple development programs focused on treating endometriosis, uterine fibroids, and preterm labor. ObsEva is supported by For more information, please visit www.ObsEva.com.
CONTACT: MEDIA CONTACT
Gretchen Schweitzer or Blair Atkinson
MacDougall Biomedical Communications
Direct: +49 172 861 8540 or +1 812 454 6257
Main: +49 89 2424 3494 or +1 781 235 3060
gschweitzer@macbiocom.com
COMPANY CONTACT
Delphine Renaud
ObsEva CEO Office
+41 22 552 1550
delphine.renaud@obseva.ch
IR CONTACT
Amy Conrad
Juniper Point
+1 858 914 1962
Amy@juniper-point.com
